Market-Moving News for October 11th
Portfolio Pulse from ryanfaloona@benzinga.com
Tempest Therapeutics (TPST) released new data showing superiority of TPST-1120 across multiple study endpoints, causing a 440% increase in its stock. Phio Pharmaceuticals (PHIO) presented new data for targeting BRD4 with its INTASYL™ Compound PH-894, leading to a 77% increase in its stock. Novo Nordisk (NVO) shares rose by 5.3% after the independent Data Monitoring Committee recommended to stop semaglutide FLOW kidney trial due to signs of early efficacy.
October 11, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk shares rose by 5.3% after the independent Data Monitoring Committee recommended to stop semaglutide FLOW kidney trial due to signs of early efficacy.
The recommendation to stop the semaglutide FLOW kidney trial due to signs of early efficacy has led to an increase in the company's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Phio Pharmaceuticals presented new data for targeting BRD4 with its INTASYL™ Compound PH-894, leading to a 77% increase in its stock.
The presentation of new data for targeting BRD4 with its INTASYL™ Compound PH-894 has led to a significant increase in the company's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100
POSITIVE IMPACT
Tempest Therapeutics released new data showing superiority of TPST-1120, leading to a 440% increase in its stock.
The release of positive data demonstrating the superiority of TPST-1120 has led to a significant increase in the company's stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100